Will Teva Pharmaceutical Industries Beat These Analyst Estimates?
Teva Pharmaceutical Industries (NYS: TEVA) is expected to report Q2 earnings on Aug. 2. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Teva Pharmaceutical Industries' revenue will expand 20.6% and EPS will increase 16.4%.
The average estimate for revenue is $5.08 billion. On the bottom line, the average EPS estimate is $1.28.
Last quarter, Teva Pharmaceutical Industries logged revenue of $5.10 billion. GAAP reported sales were 25% higher than the prior-year quarter's $4.08 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.47. GAAP EPS of $0.97 for Q1 were 15% higher than the prior-year quarter's $0.84 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 52.2%, 170 basis points worse than the prior-year quarter. Operating margin was 22.2%, about the same as the prior-year quarter. Net margin was 16.8%, 190 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $20.59 billion. The average EPS estimate is $5.38.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,484 members out of 2,553 rating the stock outperform, and 69 members rating it underperform. Among 519 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 513 give Teva Pharmaceutical Industries a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $53.48.
- Add Teva Pharmaceutical Industries to My Watchlist.
The article Will Teva Pharmaceutical Industries Beat These Analyst Estimates? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.